

# Imugene Ltd

22:39 07 Jul 2019

## Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response

Imugene Ltd (ASX:IMU) has revealed new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine showing continued positive cancer-fighting antibody and clinical response rates in patients.

Notably, the patients have maintained strong and high levels of HER-2 targeting antibodies indicating a durable response is present with no resistance developed.

In cohort 3, patients that are receiving the optimal biological dose, and selected Phase 2 dose, one patient has seen a total tumour reduction of almost 80% from baseline CT scan with one out of four of their lesions becoming unmeasurable at Day 266 visit.

Imugene managing director and chief executive officer Leslie Chong said: "This latest presentation from the HER-Vaxx Phase 1b study further reinforces the very good early results and ongoing interest among the international oncology community in our potentially promising B-cell platform cancer vaccine and clinical development strategy."

READ: Imugene presents new HER-Vaxx cancer vaccine results

The positive new data was presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona Spain over the weekend.

The data will be published in the prestigious Annals of Oncology after the congress.

New HER-Vaxx Cancer Vaccine trial data presented at the European Society of Medical Oncology World Congress on Gastrointestinal Cancer. Read more our potentially promising B-cell platform cancer vaccine and clinical development strategy #endcancer \$IMU <https://t.co/Jk5xqgEuZ0> [pic.twitter.com/BDD0Z49Jxy](https://pic.twitter.com/BDD0Z49Jxy)

— Imugene | Cancer Immunotherapies (@TeamImugene) July 7, 2019

The Phase 1b HER-Vaxx study in metastatic gastric cancer patients overexpressing the HER-2 protein completed enrolment in late 2018 and reported no safety or toxicity issues.

All evaluable patients showed increased antibody responses. The Phase 2 study began enrolment in March 2019 and is scheduled to complete in 2020.

Background

**Price:** 0.053

**Market Cap:** \$191.59 m

### 1 Year Share Price Graph



### Share Information

**Code:** IMU

**Listing:** ASX

**52 week High Low**  
0.063 0.013

**Sector:** Pharma & Biotech

**Website:** [www.imugene.com](http://www.imugene.com)

### Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

Imugene's HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.

It has been shown in pre-clinical studies and now in Phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).